(1 - 7 from 10
)
BMS' Daklinza Approved in Europe for Chronic Hepatitis C
www.genengnews.com
First pan-genotypic NS5A complex inhibitor OK'd for use in combination treatments across genotypes 1, 2, 3, and 4.
European Commission Approves Nivolumab BMS for Patients with...
www.cphi-online.com
News: European Commission Approves Nivolumab BMS for Patients with Previously-Treated Advanced Squamous NSCLC
sorted by relevance / date